Three-fraction preoperative stereotactic radiotherapy for resectable brain metastases: the phase 2 STEP trial

Clicks: 5
ID: 337933
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #284 of 286 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 286 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Postoperative stereotactic radiotherapy (SRT) is the standard adjuvant treatment after resection of brain metastases. It nevertheless requires delineation of a dynamic postsurgical cavity, delays local treatment by 3 to 6 weeks (and thus resumption of systemic therapy) and carries substantial risks of radiation necrosis and leptomeningeal disease. Preoperative SRT targets an intact lesion and may address some of these limitations. METHODS: In this open-label, single-arm, multicenter phase 2 trial, eligible adults had a Karnofsky performance status ≥70 and up to four brain metastases, including one resectable lesion ≤5 cm, from breast, non-small cell lung, kidney, or digestive cancer or melanoma. Patients received preoperative SRT (three fractions of 7.7 Gy prescribed to the encompassing 70% isodose line, equivalent to 11Gy per fraction at the isocenter) followed by surgical resection within 3 days of the last fraction. The primary outcome was 6-month local control on centrally reviewed MRI. Secondary outcomes included index-lesion radiation necrosis, leptomeningeal disease, distant intracranial control, overall survival, toxicity, cognition, and quality of life. RESULTS: Of 73 patients assessed, 67 were eligible and 63 received both SRT and surgery. Median age was 62 years. At a median follow-up of 12.7 months, the 6-month local control rate was 100% (95% CI, 95%-100%), meeting the primary endpoint; the 12-month rate was 96.4% (95% CI, 87%-99%). No leptomeningeal disease occurred. The 1-year cumulative incidence of index-lesion radiation necrosis was 7% (95% CI, 2%-16%), meeting the key secondary endpoint. Distant intracranial failure occurred in 22 patients (35%); 12-month overall survival was 81.2% (95% CI, 70%-89%). Postoperative complications occurred in 4 patients (6.3%); cognition and quality of life remained stable over the 12 months of protocol follow-up. CONCLUSIONS: Three-fraction preoperative SRT followed by resection was associated with high local control, low radiation necrosis, and no leptomeningeal disease, supporting evaluation in ongoing randomized trials.
Reference Key
openalex_W7224859256 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors J. Biau, Francois Thillays, Clara Le Fèvre, Martin Lange, Julie Villa, Mélanie Dore, A. d'Hombres, Andréa Desagneaux, L. Feuvret, Angeline Ginzac, Ioana Molnar, Johan Kristiansen, Georges Noël, Brice Leyrat, Xavier Durando, Florent Guillemin
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag267
URL
https://academic.oup.com/neuro-oncology/advance-article-pdf/doi/10.1093/neuonc/noag267/72616280/noag267.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.